Cogent Biosciences Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Andy Robbins
Chief executive officer
US$7.9m
Total compensation
| CEO salary percentage | 8.3% |
| CEO tenure | 4.1yrs |
| CEO ownership | n/a |
| Management average tenure | 3.8yrs |
| Board average tenure | 4.3yrs |
Recent management updates
Recent updates
Cogent Biosciences (NASDAQ:COGT) Is In A Good Position To Deliver On Growth Plans
Sep 04
Cogent Biosciences: Inflection Year Directly Ahead
Jun 23Cogent Biosciences (NASDAQ:COGT) Is In A Good Position To Deliver On Growth Plans
May 22Cogent Biosciences: Stock Soars On Cash Injection Ahead Of Major Data Catalyst
Feb 14Here's Why We're Watching Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation
Nov 27Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Invest In Growth?
Jun 20Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation
Mar 05Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation
Nov 18Cogent Biosciences: What's Ahead
Sep 13Cogent Biosciences: APEX Data Was Interesting, But We Need More
Jun 26Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Invest In Growth?
Jun 10Cogent Biosciences names new chief legal officer
May 03What You Need To Know About Cogent Biosciences, Inc.'s (NASDAQ:COGT) Investor Composition
Mar 17Cogent Biosciences gets Piper Sandler nod on Kiq acquisition
Dec 23Cogent Biosciences prices upsized $100M equity offering
Dec 02Cogent Bio launches $60M equity offering, shares down 7%
Nov 30Cogent Bio reports data from PLX9486 combo trial in GIST patients
Nov 18Cogent Biosciences EPS misses by $4.91
Nov 09CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$242m |
| Jun 30 2024 | n/a | n/a | -US$227m |
| Mar 31 2024 | n/a | n/a | -US$212m |
| Dec 31 2023 | US$8m | US$656k | -US$192m |
| Sep 30 2023 | n/a | n/a | -US$178m |
| Jun 30 2023 | n/a | n/a | -US$157m |
| Mar 31 2023 | n/a | n/a | -US$148m |
| Dec 31 2022 | US$4m | US$624k | -US$140m |
| Sep 30 2022 | n/a | n/a | -US$126m |
| Jun 30 2022 | n/a | n/a | -US$110m |
| Mar 31 2022 | n/a | n/a | -US$91m |
| Dec 31 2021 | US$3m | US$593k | -US$72m |
| Sep 30 2021 | n/a | n/a | -US$163m |
| Jun 30 2021 | n/a | n/a | -US$194m |
| Mar 31 2021 | n/a | n/a | -US$185m |
| Dec 31 2020 | US$18m | US$102k | -US$179m |
Compensation vs Market: Andy's total compensation ($USD7.90M) is above average for companies of similar size in the US market ($USD3.20M).
Compensation vs Earnings: Andy's compensation has increased whilst the company is unprofitable.
CEO
Andy Robbins (48 yo)
4.1yrs
Tenure
US$7,898,772
Compensation
Mr. Andrew R. Robbins, also known as Andy, M.B.A., serves as Chief Executive Officer, President and Director at of Cogent Biosciences, Inc. (formerly Unum Therapeutics Inc.) since October 23, 2020. He was...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.1yrs | US$7.90m | no data | |
| Chief Scientific Officer | 3.6yrs | US$2.98m | 0% $ 0 | |
| Chief Medical Officer | 5.4yrs | US$3.00m | 0.0012% $ 11.6k | |
| CFO & Principal Accounting Officer | 4.3yrs | US$2.14m | no data | |
| Chief Technology Officer | 4yrs | no data | no data | |
| Senior Director of Investor Relations | no data | no data | no data | |
| Chief Legal Officer & Corporate Secretary | 3.5yrs | no data | no data | |
| Chief People Officer | no data | no data | no data | |
| Senior VP of Medical Affairs & Chief Patient Officer | no data | no data | no data | |
| Senior Vice President of Chemistry | no data | no data | no data | |
| VP & Head of Clinical Development | 2yrs | no data | no data | |
| Senior VP and Head of Regulatory & Pharmacovigilance | less than a year | no data | no data |
3.8yrs
Average Tenure
48yo
Average Age
Experienced Management: COGT's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.1yrs | US$7.90m | no data | |
| Independent Director | 5.3yrs | US$345.49k | 0% $ 0 | |
| Independent Director | 5.3yrs | US$336.69k | 0% $ 0 | |
| Independent Director | 3.8yrs | US$345.80k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 6.8yrs | US$340.37k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 4.3yrs | US$341.36k | 0% $ 0 | |
| Independent Chairman of the Board | 4.3yrs | US$364.55k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 1.8yrs | no data | no data |
4.3yrs
Average Tenure
58yo
Average Age
Experienced Board: COGT's board of directors are considered experienced (4.3 years average tenure).